Use of subcutaneous and intravenous trastuzumab: real-world experience from three hospitals in Sweden
| Autor: | Thibaut Sanglier, Antonis Valachis, Milica Uhde, Bing Li, Flaminia Chiesa, Lena M. S. Carlsson, Marie Sundqvist |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Cancer Research
medicine.medical_specialty Receptor ErbB-2 Injections Subcutaneous Breast Neoplasms 03 medical and health sciences Antineoplastic Agents Immunological 0302 clinical medicine Breast cancer Trastuzumab Internal medicine Outcome Assessment Health Care Electronic Health Records Humans Medicine 030212 general & internal medicine skin and connective tissue diseases neoplasms Aged Retrospective Studies Early breast cancer Sweden business.industry Medical record Retrospective cohort study General Medicine Middle Aged medicine.disease Oncology 030220 oncology & carcinogenesis Administration Intravenous Female business medicine.drug |
| Zdroj: | Future Oncology. 15:2733-2741 |
| ISSN: | 1744-8301 1479-6694 |
| DOI: | 10.2217/fon-2019-0160 |
| Popis: | Aim: We aimed to describe the use of subcutaneous (sc.) trastuzumab use in a real-world setting. Patients & methods: This retrospective cohort study evaluated electronic medical records of patients with early breast cancer and trastuzumab use from January 2010 to February 2018 in three hospitals in Sweden. Results: In total, 363 patients received trastuzumab during study period. Of these, 217 (59.8%) patients started treatment with sc. trastuzumab and 146 (40.2%) with intravenous trastuzumab. After sc. trastuzumab approval, use of sc. trastuzumab increased from 70.2% in 2014 to 100% in 2017. Since 2013, 34 of 35 (97.4%) patients who started with intravenous trastuzumab switched to sc. formulation. Conclusion: Trastuzumab sc. quickly became the prevailing formulation for treatment in HER2-positive early breast cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|